Clinical Trial: Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome : a Pilot Randomized, Placebo-controlled Study

Brief Summary:

Several studies report association between restless legs syndrome (RLS), HTA and cardiovascular diseases .

The mechanisms involved in this relationship remained unknown, but several evidences favor the role of periodic limb movements in sleep (PLMS), patterns frequently associated with RLS. Sympathetic overactivity is associated with PLMS with increased pulse rate and blood pressure coincident with PLMS. PLMS-related repetitive nocturnal blood pressure fluctuations could contribute to the risk of high blood pressure, heart disease, and stroke in patients with RLS, especially in the elderly. Several studies already reported that dopaminergic agonists reduce the severity of RLS and the PLMS index.

Do dopaminergic agonists reduce the risk of cardiovascular diseases and associated autonomic dysfunctions in patients with RLS? Nocturnal BP (blood pressure) decline has major clinical implications, and the loss of normal reduction in BP during sleep is associated with high risk of cardiovascular morbidity and mortality.

The main aim of this study was to evaluate the impact of rotigotine patch treatment on validated cardiovascular risk factors ambulatory BP during night, day and night-to-day ratio, and endothelial function in patients with idiopathic RLS compared to placebo.


Detailed Summary:
Sponsor: University Hospital, Montpellier

Current Primary Outcome: Percentages of non-dippers(defined as <10% drop in BP during sleep)at 35+/-3 days [ Time Frame: 35 +/- 3 day ]

Percentages of non-dippers is defined as <10% drop in blood pressure (BP) during sleep (24h ambulatory BP monitoring).


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Digital pulse amplitude measured by reactive hyperhemia with finger plethysmographic methodology [ Time Frame: day 35 +/- 3 ]
    Fasting morning peripheral arterial tonometry (PAT)
  • PLMS and PLMS-microarousal indexes [ Time Frame: day 35 +/- 3 ]
    Nocturnal polysomnography (PSG)
  • Amplitude of PLMS-related HR responses [ Time Frame: day 35 +/- 3 ]
    Nocturnal polysomnography (PSG)


Original Secondary Outcome: Same as current

Information By: University Hospital, Montpellier

Dates:
Date Received: March 22, 2013
Date Started: December 2012
Date Completion: December 2015
Last Updated: April 2, 2013
Last Verified: March 2013